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ABSTRACT 
 
NKX3.1 is a tumor suppressor frequently lost in prostate cancer. Previous studies by others 
indicated that the risks associated with reduced NKX3.1 levels can be enhanced by anti-oxidant 
supplementation. Selenium is an essential component of several proteins with anti-oxidant 
functions and lower levels of selenium have been associated with greater risk of prostate cancer. 
In contrast, participants of the SELECT prostate cancer prevention trial were at increased risk of 
prostate cancer when supplemented with selenium when their baseline selenium levels were high. 
In order to investigate whether there was an interaction between a functional polymorphism in 
NKX3.1 that results in less protein and selenium status with prostate cancer grade or outcome, 
plasma selenium levels and the genotypes of NKX3.1 and the selenium carrier protein SELENOP 
were determined from a cohort of men who underwent radical protatectomy. NKX3.1 and 
SELENOP genotypes were associated with a more aggressive prostate tumor grade at the time of 
prostatectomy, but there were no significant interactions of NKX3.1 genotype with either 
selenium status or SELENOP genotype. There was also a significant association between NKX3.1 
genotype and prostate cancer recurrence, however this association was modified by SELENOP 
genotype, but not with plasma selenium levels. These data indicate that the impact of selenium 
status on prostate cancer may be influenced by factors other than the amount of selenium in 
circulation. 
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1.  INTRODUCTION 
 
The use of dietary supplements for the prevention of prostate cancer has been evaluated in 
randomized clinical trials. One supplement that has received attention for this purpose due to 
encouraging in vitro, in vivo and clinical trials is vitamin E (reviewed in1). Data obtained from 
the Alpha-Tocopherol, Beta-Carotene Cancer Prevention trial (ATBC) indicated that 
supplementation with alpha-tocopherol reduced the incidence of prostate cancer with an RR of 
0.88 (95% CI, 0.76-1.03)2. Selenium, an essential micronutrient previously considered to be an 
excellent candidate for prostate cancer chemoprevention, was evaluated in the Nutritional 
Prevention of Cancer Trial (NPCT)3. Using selenium-enriched yeast as a source of selenium, 
there was a significant reduction in prostate cancer incidence in the selenium group among 
participants with lower plasma selenium at baseline. Based on these data and supporting results 
from in vitro and preclinical studies, the larger multicenter Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) was initiated to evaluate whether vitamin E and selenium, alone or in 
combination, were effective in preventing prostate cancer.  Men who were cancer-free at baseline 
were randomized to one of four groups: 200µg/day of selenomethionine, 400 IU/day of vitamin E 
(a-tocopherol), both or placebo4. The trial was terminated early due to the lack of evidence that 
either supplement reduced prostate cancer risk and because participants in the Vitamin E arm 
exhibited increased prostate cancer incidence5. Subsequent analysis indicated that men assigned 
to the selenium arm who had higher baseline selenium levels were also at increased risk of high-
grade prostate cancer6. Although selenium in its elemental form is not an anti-oxidant, it 
indirectly contributes to anti-oxidant defenses due to its role as an essential component of several 
anti-oxidant enzymes that contain selenocysteine7. Thus, two anti-oxidants, vitamin E and 
selenium, may in some circumstances contribute to the elevated risk of prostate cancer. 
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An unexpected effect of anti-oxidant supplementation was revealed when mice null for 
the NKX3.1 tumor suppressor were used to investigate the impact of anti-oxidant 
supplementation on prostate pathology8. The diet of these mice was supplemented with the anti-
oxidant N-acetylcysteine (NACS) and consequential effects on prostatic hyperplasia, dysplasia 
and prostatic intraepithelial neoplasia (PIN) were determined8. NKX3.1 is encoded by an 
androgen-regulated homeobox gene expressed specifically in the prostate gland and located in the 
chromosome 8p219, a region frequently exhibiting loss of heterozygosity in human prostate 
cancers10,11. Although treatment of the NKX3.1-null mice with NACS reduced reactive oxygen 
species (ROS), there was increased proliferation of prostate epithelium proliferation in the 
NACS-treated mice8. Given these results, these same authors extended their animal data to 
investigate whether NKX3.1 genotype was associated with the development of prostate cancer 
among men provided vitamin E or selenium in participants of SELECT12. DNAs were genotyped 
for a functional single nucleotide polymorphism (SNP) in the NKX3.1 promoter (rs17881886) 
where the presence of the minor C allele results in its lower mRNA expression by altering the 
binding of the SP1 transcription factor to the 5’-untranslated region (UTR) of the gene10. While 
no effect of NKX3.1 genotype on prostate cancer risk was found, these studies revealed a 
significant interaction between the minor C allele in NKX3.1 with either selenium and vitamin E 
supplementation. In the selenium-supplemented group, the NKX3.1 rare genotype was associated 
with a 67% increased risk for total prostate cancer and with an 81% increased risk for low-grade 
prostate cancer12.  Based on these data, we examined whether there were associations between 
NKX3.1 genotype and selenium status with cancer grade at presentation or recurrence of disease 
following prostatectomy in a Chicago area cohort.   
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2. MATERIALS AND METHODS 
 
2.1 Study Population 
 
The cohort used in this study was part of the Adiposity and Outcomes of Clinically Localized 
Prostate Study, a prospective cohort investigating the impact of obesity on biochemical failure and 
other adverse outcomes after radical prostatectomy for clinically localized prostate cancer. A total 
of 129 volunteers were selected in the Chicago area. Participants were mostly middle-aged (mean 
= 60 years) and Caucasian (67%). Before surgery, blood samples and buffy coat DNA were 
collected and clinical status, lifestyle and anthropometric measures were assessed. Tumor 
diagnoses were determined by a single pathologist and a second pathologist reviewed 10% of 
samples (see reference13 for details). The protocol was approved by the UIC Office for the 
Protection of Research Subjects.  
 
2.2 Biochemical follow-up 
 
After prostatectomy, volunteers were instructed to repeat the serum PSA (prostate-specific antigen) 
test every 3 months for the first year, every 3-6 months for the second year and once a year 
thereafter. Serum PSA concentration was determined using the Tandem PSA monoclonal antibody 
assay (Hybritech, San Diego, CA). Tumor recurrence within two years, previously shown to be 
associated with increased risk of distant metastasis and prostate cancer-specific mortality14,15, was 
defined as detectable (≥ 0.1 ng/mL) and subsequently rising serum PSA.  
 
2.3 Genotyping 
 
Archived DNA were originally obtained from buffy coat samples and genotyping of the NKX3.1 
rs11781886 was performed by real-time PCR using the QuantStudio 6K Real-Time PCR System 
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with Taqman SNP Genotyping Assays (Applied Biosystems, Thermo Scientific, Foster City, CA, 
USA). Allelic discrimination was obtained by performing an endpoint read using the Taqman 
Genotyper software. Validation was done by randomly sequencing 10% of the samples which were 
in agreement with the PCR generated results. Genotyping for rs7579 and rs3877899 in SELENOP 
and plasma selenium concentrations were previously reported on the same sample set as was used 
in this study13.  
  
2.4 Statistical analysis 
 
Bivariate associations were evaluated using Fisher’s Exact Test (Supplemental Table S1). The two 
main outcomes variables for this study were Gleason Score and tumor recurrence. Patients were 
divided into groups based on their Gleason Score sums divided as: 2 to 6, 7(3+4), 7(4+3) and ≥8, 
and cancer recurrence status after surgery (yes and no). An ordinary logistic regression model was 
used for outcome Gleason Score with the lower category (2 to 6) set as the reference, whereas a 
logistic regression model was used for tumor recurrence. In both models, a hypothesis based model 
was tested with the main goal of investigating the associations of NKX3.1 SNP with selenium status 
on tumor grade and recurrence. The predictors of primary interest were plasma selenium, NKX3.1 
rs11781886, SELENOP rs3877899, SELENOP rs7579, interaction of selenium status with NKX3.1, 
and of NKX3.1 with both SELENOP SNPs. A backwards selection was performed for demographic 
variables. The models were adjusted for age, body fat and race. Odds ratio, 95% confidence limits 
and p values are provided. All tests are two sided and with the significance level of 0.05. All 
statistical analyses were performed using R statistical software.  
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3. RESULTS 
 
3.1 A polymorphism in NKX3.1 is not associated with an increased chance of being 
diagnosed a more aggressive prostate cancer. 
 
DNA obtained from men diagnosed with prostate cancer and participating in the Adiposity and 
Outcomes of Clinically Localized Prostate Study were genotyped for the functional 
polymorphism in the NKX3.1 promoter (rs11781886). Overall, the genotypes frequencies for 
rs11781886 were 56% TT, 40% TC and 4% CC. Mean plasma selenium concentration (134.2 ± 
24.8 ng/ml) and serum PSA (7.5 ± 6.3 ng/ml) were previously reported13. Biomarkers 
concentrations and the frequencies of Gleason score groups and recurrence status were not 
different between NKX3.1 genotypes. The allele frequencies did not differ between African 
American and Caucasian men, as well as patient groups with different Gleason scores or tumor 
recurrence after prostatectomy (Supplemental Table S1).  
Using ordinary multivariate logistic regression model, the odds of a higher Gleason sum 
increased with plasma selenium levels and NKX3.1 C genotype (Table 1). However, there was no 
interaction between NKX3.1 genotype and selenium status with Gleason grade. Selenoprotein P 
(SELENOP) is the most abundant selenium-containing protein in plasma and the main selenium 
transporter in plasma16,17. Two functional SNPs in SELENOP, rs3877899 resulting in either an 
alanine or threonine in the coding region and rs7579 resulting in a G or A in the 3-untranslated 
region of the SELENOP gene, have been shown to impact plasma selenium levels and SELENOP 
concentrations as well as the levels of selenoproteins in plasma, erythrocytes and 
lymphocytes18,19. Associations between these polymorphisms and Gleason sum scores were 
assessed by combining the low frequency alleles (SELENOP rs3877899GA+AA and SELENOP 
rs7579GA+AA, respectively).  There was a 3-fold higher risk (p = 0.019) of aggressive cancer in 
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men with SELENOP rs7579GA+AA genotype compared to SELENOP rs7579GG genotype ((OR 
[95% CI] = 3.02 [1.21 – 7.76]) while no association with the SELENOP rs3877899 
polymorphism was observed (Table 1). Examining the data for an interaction between 
polymorphisms in NKX3.1 and SELENOP, there was no interaction of the NKX3.1 polymorphism 
with either SELENOP rs3877899 or SELENOP rs7579 (Table 1).  
3.2 NKX3.1 and SELENOP genotype are associated with an increased risk of prostate cancer 
recurrence following prostatectomy.  
We previously reported the association of the SELENOP rs3877899AA genotype status with 
prostate cancer recurrence in the same population as assessed here13. This observation was 
extended by testing for associations with tumor recurrence, defined as detectable (≥ 0.01 ng/mL) 
and rising serum PSA, with SNPs in NKX3.1 and SELENOP genes as well as selenium levels (Table 
2). Multivariate logistic regression model with backwards selection was used to assess such 
associations. There was significant interaction effect between NKX3.1 and SELENOP rs3877899. 
When present with the SELENOP rs3877899GG genotype, NKX3.1TC+CC is significantly more 
protective against cancer recurrence (NKX3.1TC+CC vs.  NKX3.1TT OR = 0.19, or NKX3.1TT versus 
NKX3.1TC+CC OR = 5.3, p-value = 0.0183). This protective effect of NKX3.1TC+CC was not found 
when SELENOP rs3877899GA+AA. In contrast, SELENOP rs3877899GA+AA was associated with 
increased risk of recurrence co-expressed with NKX3.1TC+CC (OR = 4.85, p-value = 0.0415). No 
significant association between SELENOP rs3877899GA+AA and NKX3.1TT was found with prostate 
cancer recurrence. 
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DISCUSSION 
The benefits of dietary anti-oxidant supplements remain uncertain due to conflicting results 
from epidemiological data, involving dietary intake and disease incidence, compared to 
supplementation trials, comprised of selected groups at elevated risk. Baseline status of an 
individual and the effects of an individual’s genetic background may influence the consequences 
of consuming anti-oxidant supplements for cancer prevention. Previously published work indicated 
that the impact of the allelic identity of the NKX3.1 gene on prostate cancer might be influenced 
by anti-oxidant intake or status8,12. These data were expanded here by examining whether serum 
selenium levels together with NKX3.1 genotype were associated with either the aggressiveness of 
the tumor at the time of diagnosis or cancer recurrence following prostatectomy. No interaction 
between selenium status and NKX3.1 genotype on either of these endpoints were found for the 
cohort of men who had undergone prostatectomy examined in this study. 
 Selenium status in a particular tissue may not reflect the levels determined from serum or 
plasma. For example, we previously reported a lack of association between serum selenium levels 
and the selenium concentration from prostate tissue20.  Prostate tissue was not available for the men 
from this cohort examined, but we instead examined the genotype of the major selenium carrier 
protein, SELENOP, determining the allelic identity of SNPs previously shown to be functional and 
influence the levels of SELENOP18,19. The rare allele A of rs7579 in the SELENOP 3’-untranslated 
region, was associated with an increased risk of aggressive cancer, but not when co-expressed with 
NKX3.1 rs11781886 minor allele C (Table 1). Moreover, the rare allele A for SELENOP rs3877899 
was associated with an increased risk of recurrence of cancer only when co-expressed with the 
minor allele C for NKX3.1 SNP (Table 2).  
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SELENOP, which contains 10 selenium atoms in the form of selenocysteine, is generated 
in the liver, enters the circulation and can gain entry into tissues by megalin, a carrier protein with 
many ligands, where SELENOP is hydrolyzed, releasing selenium for eventual use in the synthesis 
of prostatic selenoproteins17,21. Polymorphisms in SELENOP have been shown to be associated 
with prostate cancer risk22,23 and interact with polymorphisms in the MnSOD anti-oxidant gene to 
further increase prostate cancer risk24. The lack of association between circulating and tissue 
selenium levels20 and the association between NKX3.1 genotype and SELENOP polymorphisms 
but not between NKX3.1 genotype and plasma selenium levels indicate that the efficiency or 
regulation of selenium transport may be relevant to understanding the effects of selenium on 
prostate cancer. Although megalin can transport many ligands in addition to selenium, it is 
interesting to note that polymorphisms in the megalin gene were significantly associated with both 
prostate cancer recurrence and mortality25.  
NKX3.1 is a transcription factor that has been implicated in prostate cancer due to its 
frequent deletion of its gene in the disease and its loss being associated with more aggressive 
disease9,26,27. It regulates several anti-oxidant enzymes and the loss of NKX3.1 results in 
increased oxidative damage28.  Here, we have shown that the SNPs in NKX3.1 and SELENOP, 
that are likely to result in reduced levels of each of those proteins, interact to increase the risk of 
prostate cancer recurrence (Table 2). It is therefore possible that the reduction of both NKX3.1 
and SELENOP results in elevated oxidative stress due to diminished expression of NKX3.1-
regulated anti-oxidant genes, as well as reduced levels of anti-oxidant selenoproteins, resulting in 
growth promoting reactive oxygen signaling and accelerated accumulation of mutations that 
contribute to progression. 
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In summary, both NKX3.1 and SELENOP genotypes were associated with a more 
aggressive prostate tumor grade at the time of prostatectomy, but there were no significant 
interactions of NKX3.1 genotype with either selenium status or SELENOP genotype. There was 
also a significant association between NKX3.1 genotype and prostate cancer recurrence although 
this association was modified by SELENOP genotype, but not with plasma selenium levels. 
Weaknesses of the study include the small sample size and the relatively short period of follow 
up.  In addition, the study was not originally designed to investigate the particular endpoints 
reported herein, raising the possibility that there were confounding factors that were not taken 
into account in the analyses.  While additional studies with larger cohorts and longer follow up 
are warranted, these data indicate that the impact of selenium on prostate cancer risk and outcome 
needs to consider the levels of selenium in prostatic tissue, which may be influenced by selenium 
transport and metabolism. 
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TABLE 1 Associations of higher tumor Gleason grade groupa with selenium, NKX3.1 and 
SELENOP genotypes. 
 
Selenium, NKX3.1 and SELENOP genotypes CORb (95% CI) P value 
Selenium 1.01 (1.00-1.03) 0.046 
NKX3.1 rs11781886TC+CC 2.12 (0.86-5.33) 0.010 
SELENOP rs3877899GA+AA - - 
SELENOP rs7579GA+AA 3.02 (1.21-7.76) 0.019 
Selenium * rs11781886TC+CC - - 
NKX3.1 * SELENOP rs3877899 - - 
NKX3.1 * SELENOP rs7579 0.31 (0.07-1.21) 0.094 
COR: cumulative odds ratio; CI: confidence interval. 
a: Gleason sums were categorized in to four Gleason grade groups (2 to 6, 7 [3+4], 7 [4+3] and ≥8) based on the 8th 
Edition of the American Joint Commission on Cancer  tumor-node-metastasis staging for prostate cancer (Amin MB, 
Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. American Joint Committee on Cancer. Switzerland: 
Springer; 2017). 
b: CORs were derived using ordinal multivariate logistic regression with backwards selection of selenium, NKX3, and 
SELENOP genotypes and interaction terms followed by further adjustment for age, race and body fat mass. After 
backwards selection, the model was: Gleason grade group (1 to 4) =  β1NKX3 + β2SELENOP rs7579 + 
 β3NKX3*SELENOP rs7579 + ε.  
 
 
  
TABLE 2.   Interaction of NKX3.1 and SELENOP genotypes with biochemical recurrence. 
 
Tumor Recurrence a Estimates (SE) p-value 
NKX3.1TC+CC -1.62 (0.68) 0.018 
SELENOP rs3877899GA+AA -0.80 (0.59) 0.173 
NKX3.1 * selenium - - 
NKX3,1 * SELENOP rs7579 - - 
NKX3.1 TC+CC * SELENOP rs3877899GA+AA 2.38 (0.97) 0.041 
 OR (95% CI) p-value 
NKX3.1TC+CC (at SELENOP rs3877GG) 
NKX3.1TC+CC (at SELENOP rs3877GA+AA) 
0.19 (0.04-0.68) 
2.14 (0.55-8.31) 
0.0183 
0.2704 
SELENOP rs3877899GA+AA (at NKX3.1TT) 0.45 (0.14-1.43) 0.1734 
SELENOP rs3877899GA+AA (at NKX3.1TC+CC) 4.85 (1.06-22.19) 0.0415 
 
OR: odds ratio; CI: confidence interval. 
Tumor recurrence was defined as detectable (0.1ng/L) and rising serum PSA levels or additional 
therapy. 
a: Multivariate Logistic Model; after backwards selection: Recurrence (yes x no) =  β1NKX3 
+ β2SELENOP rs3877899 +  β3NKX3*SELENOP rs3877899. 
b: OR for individuals with NKX3.1 minor allele C to have tumor recurrence if also carrying rare 
allele A for SELENOP rs3877899 
c: OR for individuals with SELENOP rs3877899 minor allele A to have tumor recurrence if also 
carrying rare allele C for NKX3.1 
Significant p values are highlighted in bold and italic 
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Supplemental Table S1 
Distribution of NKX3.1 genotype according to race and prostate cancer biomarkers  
 rs11781886 (NKX3) 
p value 
 TC+CC (N= 57) TT (N= 72) 
Race    
African American 16 (55.2%) 13 (44.8%) 0.252 
Caucasian 35 (39.3%) 54 (60.7%)  
Other 6 (54.5%) 5 (45.5%)  
Gleason score    
8 or higher 2 (3.5%) 5 (6.9%) 0.425 
7 (4+3) 6 (10.5%) 6 (8.3%)  
7 (3+4) 29 (50.9%) 28 (38.9%)  
2 to 6 20 (35.1%) 33 (45.8%)  
Recurrencea    
yes 9 (15.8%) 18 (25%) 0.289 
no 48 (84.2%) 54 (75%)  
PSA (ng/mL) 7.7 ± 5.1 7.3 ± 7.1 0.149 
Plasma Se (µg/L) 132.1 ± 26.9 135.8 ± 23.0 0.407 
 
 
Values are N (%) for categorical variables  
a: Detectable (≥ 0.01 ng/ml) and rising serum PSA[24] 
 
